Contents
1Name#
(1)This instrument is the National Health (Minimum Stockholding) Amendment Determination (No. 10) 2026.
(2)This instrument may also be cited as PB 134 of 2026.
2Commencement#
| Commencement information | ||
|---|---|---|
| Column 1 | Column 2 | Column 3 |
| Provisions | Commencement | Date/Details |
| 1. Sections 1 to 4 and anything in this instrument not elsewhere covered by this table | 1 November 2026. | 1 November 2026 |
| 2. Schedule 1 | 1 November 2026. | 1 November 2026 |
| 3. Schedule 2 | 1 April 2027. | 1 April 2027 |
(2)Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.
4Schedules#
Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.
Schedule 1 · Amendments commencing 1 November 2026
National Health (Minimum Stockholding) Determination 2023#
1 Schedule 1 (table)
After:
| Aripiprazole | Tablet 15 mg | Oral | APO-Aripiprazole | 3 months stock by reference to usual demand |
insert:
| Aripiprazole | Tablet 15 mg | Oral | ARIPIPRAZOLE-WGR | between 1 November 2026 and 30 April 2027—0 months stock by reference to usual demand |
2 Schedule 1 (table)
Omit:
| Aripiprazole | Tablet 30 mg | Oral | ARIPIPRAZOLE-WGR | between 1 July 2026 to 31 October 2026—0 months stock by reference to usual demand |
3 Schedule 1 (table)
After:
| Atomoxetine | Capsule 80 mg (as hydrochloride) | Oral | APO-Atomoxetine | 3 months stock by reference to usual demand |
insert:
| Atropine | Eye drops containing atropine sulfate monohydrate 10 mg per mL, 15 mL | Application to the Eye | Atropt | 6 months stock by reference to usual PBS demand |
4 Schedule 1 (table)
After:
| Calcium | Tablet, chewable, 500 mg (as carbonate) | Oral | Cal-500 | 6 months stock by reference to usual PBS demand |
insert:
| Capecitabine | Tablet 500 mg | Oral | Xelabine | 4 months stock by reference to usual demand until 31 March 2027 |
5 Schedule 1 (table)
After:
| Ceftriaxone | Powder for injection 2 g (as sodium) | Injection | Ceftriaxone Viatris | 6 months stock by reference to usual demand |
insert:
| Cefuroxime | Tablet 250 mg (as axetil) | Oral | Zinnat | between 1 November 2026 and 31 December 2026—0 months stock by reference to usual demand |
6 Schedule 1 (table)
After:
| Dolutegravir with abacavir and lamivudine | Tablet containing dolutegravir 50 mg with abacavir 600 mg and lamivudine 300 mg | Oral | Triumeq | 6 months stock by reference to usual PBS demand |
insert:
| Dorzolamide with timolol | Eye drops containing dorzolamide 20 mg (as hydrochloride) with timolol 5 mg (as maleate) per mL, 5 mL | Application to the Eye | Cosdor | 4 months stock by reference to usual demand until 31 March 2027 |
| Dorzolamide with timolol | Eye drops containing dorzolamide 20 mg (as hydrochloride) with timolol 5 mg (as maleate) per mL, 5 mL | Application to the Eye | Cosopt | 4 months stock by reference to usual demand until 31 March 2027 |
| Dorzolamide with timolol | Eye drops containing dorzolamide 20 mg (as hydrochloride) with timolol 5 mg (as maleate) per mL, 5 mL | Application to the Eye | Vizo-PF Dorzolatim | 4 months stock by reference to usual demand until 31 March 2027 |
7 Schedule 1 (table)
After:
| Estradiol with norethisterone | Transdermal patches containing 620 micrograms estradiol (as hemihydrate) with 2.7 mg norethisterone acetate, 8 | Transdermal | Estalis continuous 50/140 | 6 months stock by reference to usual PBS demand |
insert:
| Etoposide | Powder for I.V. infusion 1 g (as phosphate) | Injection | Etopophos | 4 months stock by reference to usual demand until 31 March 2027 |
8 Schedule 1 (table)
After:
| Fluconazole | Powder for oral suspension 50 mg in 5 mL, 35 mL | Oral | Diflucan | 4 months stock by reference to usual PBS demand |
insert:
| Fludarabine | Solution for I.V. injection 50 mg fludarabine phosphate in 2 mL | Injection | Fludarabine Ebewe | between 1 November 2026 and 31 November 2026—0 months stock by reference to usual demand |
9 Schedule 1 (table)
After:
| Glimepiride | Tablet 2 mg | Oral | ARX-GLIMEPIRIDE | 6 months stock by reference to usual demand |
insert:
| Glimepiride | Tablet 2 mg | Oral | GLIMEPIRIDE-WGR | between 1 November 2026 and 31 March 2027—0 months stock by reference to usual demand |
10 Schedule 1 (table)
Omit:
| Insect allergen extract-yellow jacket venom | Injection set containing 550 micrograms | Injection | Albey Yellow Jacket Venom | 6 months stock by reference to usual PBS demand of Insect allergen extract-yellow jacket venom, Injection set containing 550 micrograms with diluent, Injection (Hymenoptera Yellow Jacket Venom) and Insect allergen extract-yellow jacket venom, Injection set containing 550 micrograms, Injection (Albey Yellow Jacket Venom) |
insert:
| Insect allergen extract-yellow jacket venom | Injection set containing 550 micrograms | Injection | Albey Yellow Jacket Venom | 6 months stock by reference to usual PBS demand |
11 Schedule 1 (table)
Omit:
| Meloxicam | Capsule 15 mg | Oral | Mobic | between 1 September 2026 to 31 October 2026—0 months stock by reference to usual demand |
12 Schedule 1 (table)
Omit:
| Olanzapine | Tablet 15 mg (orally disintegrating) | Oral | OLANZAPINE ODT-WGR | between 1 May 2026 to 31 October 2026—0 months stock by reference to usual demand |
13 Schedule 1 (table)
Omit:
| Olanzapine | Tablet 5 mg (orally disintegrating) | Oral | OLANZAPINE ODT-WGR | between 1 May 2026 to 31 October 2026—0 months stock by reference to usual demand |
14 Schedule 1 (table)
After:
| Ondansetron | Tablet 4 mg (as hydrochloride dihydrate) | Oral | Ondansetron Tablets Viatris | 6 months stock by reference to usual demand |
insert:
| Oxaliplatin | Solution concentrate for I.V. infusion 100 mg in 20 mL | Injection | Oxaliplatin Accord | 4 months stock by reference to usual demand until 31 March 2027 |
| Oxaliplatin | Solution concentrate for I.V. infusion 100 mg in 20 mL | Injection | OXALIPLATIN BAXTER | 4 months stock by reference to usual demand until 31 March 2027 |
15 Schedule 1 (table)
Omit:
| Paraffin | Pack containing 2 tubes eye ointment, compound, containing white soft paraffin with liquid paraffin, 3.5 g | Application to the eye | Poly Visc | Between 1 October 2026 and 28 February 2027—0 months stock by reference to usual demand |
16 Schedule 1 (table)
After:
| Perindopril | Tablet containing perindopril erbumine 2 mg | Oral | PERISYL | 6 months stock by reference to usual demand |
insert:
| Perindopril | Tablet containing perindopril erbumine 4 mg | Oral | PERINDOPRIL-WGR | between 1 November 2026 and 31 March 2027—0 months stock by reference to usual demand |
17 Schedule 1 (table)
Omit:
| Promethazine | Injection containing promethazine hydrochloride 50 mg in 2 mL | Injection | DBL Promethazine Hydrochloride | 6 months stock by reference to usual PBS demand |
18 Schedule 1 (table)
After:
| Sumatriptan | Tablet 50 mg (as succinate) | Oral | APO-Sumatriptan | 4 months stock by reference to usual demand |
insert:
| Tacrolimus | Capsule 0.5 mg | Oral | Pacrolim | 4 months stock by reference to usual demand until 31 March 2027 |
| Tacrolimus | Capsule 0.5 mg | Oral | Pharmacor Tacrolimus 0.5 | 4 months stock by reference to usual demand until 31 March 2027 |
| Tacrolimus | Capsule 0.5 mg | Oral | Prograf | 4 months stock by reference to usual demand until 31 March 2027 |
| Tacrolimus | Capsule 0.5 mg | Oral | Tacrograf | 4 months stock by reference to usual demand until 31 March 2027 |
| Tacrolimus | Capsule 0.5 mg | Oral | Tacrolimus Sandoz | 4 months stock by reference to usual demand until 31 March 2027 |
| Tacrolimus | Capsule 1 mg | Oral | Pacrolim | 4 months stock by reference to usual demand until 31 March 2027 |
| Tacrolimus | Capsule 1 mg | Oral | Pharmacor Tacrolimus 1 | 4 months stock by reference to usual demand until 31 March 2027 |
| Tacrolimus | Capsule 1 mg | Oral | Prograf | 4 months stock by reference to usual demand until 31 March 2027 |
19 Schedule 1 (table)
After:
| Tacrolimus | Capsule 1 mg | Oral | Tacrograf | 3 months stock by reference to usual demand |
insert:
| Tacrolimus | Capsule 1 mg | Oral | Tacrolimus Sandoz | 4 months stock by reference to usual demand until 31 March 2027 |
| Tacrolimus | Capsule 1 mg (once daily prolonged release) | Oral | ADVAGRAF XL | 4 months stock by reference to usual demand until 31 March 2027 |
| Tacrolimus | Capsule 1 mg (once daily prolonged release) | Oral | Tacrolimus XR Sandoz | 4 months stock by reference to usual demand until 31 March 2027 |
| Tacrolimus | Capsule 3 mg (once daily prolonged release) | Oral | ADVAGRAF XL | 4 months stock by reference to usual demand until 31 March 2027 |
| Tacrolimus | Capsule 3 mg (once daily prolonged release) | Oral | Tacrolimus XR Sandoz | 4 months stock by reference to usual demand until 31 March 2027 |
| Tacrolimus | Capsule 5 mg | Oral | Pharmacor Tacrolimus 5 | 4 months stock by reference to usual demand until 31 March 2027 |
| Tacrolimus | Capsule 5 mg | Oral | Prograf | 4 months stock by reference to usual demand until 31 March 2027 |
20 Schedule 1 (table)
After:
| Tacrolimus | Capsule 5 mg | Oral | Tacrograf | 3 months stock by reference to usual demand |
insert:
| Tacrolimus | Capsule 5 mg | Oral | Tacrolimus Sandoz | 4 months stock by reference to usual demand until 31 March 2027 |
| Tacrolimus | Capsule 5 mg (once daily prolonged release) | Oral | ADVAGRAF XL | 4 months stock by reference to usual demand until 31 March 2027 |
| Tacrolimus | Capsule 5 mg (once daily prolonged release) | Oral | Tacrolimus XR Sandoz | 4 months stock by reference to usual demand until 31 March 2027 |
Schedule 2 · Amendments commencing 1 April 2027
National Health (Minimum Stockholding) Determination 2023#
1 Schedule 1 (table)
After:
| Captopril | Oral solution 5 mg per mL, 95 mL | Oral | Capoten | 4 months stock by reference to usual PBS demand |
insert:
| Carbamazepine | Oral suspension 100 mg per 5 mL, 300 mL | Oral | Tegretol Liquid | 6 months stock by reference to usual PBS demand |
2 Schedule 1 (table)
After:
| Codeine | Tablet containing codeine phosphate hemihydrate 30 mg | Oral | Aspen Pharmacare Australia Pty Ltd | 4 months stock by reference to usual PBS demand |
insert:
| Colestyramine | Sachets containing 4.7 g oral powder (equivalent to 4 g colestyramine), 50 | Oral | Questran Lite | 6 months stock by reference to usual PBS demand |
3 Schedule 1 (table)
After:
| Lithium | Tablet containing lithium carbonate 450 mg (slow release) | Oral | Quilonum SR | 6 months stock by reference to usual PBS demand |
insert:
| Mecasermin | Solution for injection 40 mg in 4 mL (10 mg per mL) | Injection | Increlex | 6 months stock by reference to usual PBS demand |
4 Schedule 1 (table)
After:
| Meloxicam | Tablet 7.5 mg | Oral | MELOBIC | 4 months stock by reference to usual demand |
insert:
| Mercaptopurine | Oral suspension containing mercaptopurine monohydrate 20 mg per mL, 100 mL | Oral | Allmercap | 6 months stock by reference to usual PBS demand |
5 Schedule 1 (table)
After:
| Metoprolol | Tablet containing metoprolol tartrate 100 mg | Oral | Metrol 100 | 4 months stock by reference to usual demand |
insert:
| Metronidazole | Oral suspension containing metronidazole benzoate 320 mg per 5 mL, 100 mL | Oral | Flagyl S | 6 months stock by reference to usual PBS demand |
6 Schedule 1 (table)
After:
| Nortriptyline | Tablet 25 mg (as hydrochloride) | Oral | Allegron | between 1 June 2026 to 30 November 2026—4 months stock by reference to usual demand |
insert:
| Nystatin | Capsule 500,000 units | Oral | Nilstat | 6 months stock by reference to usual PBS demand |
| Nystatin | Tablet 500,000 units | Oral | Nilstat | 6 months stock by reference to usual PBS demand |
7 Schedule 1 (table)
After:
| Peginterferon alfa-2a | Injection 180 micrograms in 0.5 mL single use pre-filled syringe | Injection | Pegasys | 6 months stock by reference to usual PBS demand |
insert:
| Penicillamine | Tablet 125 mg | Oral | D-Penamine | 6 months stock by reference to usual PBS demand |
| Penicillamine | Tablet 250 mg | Oral | D-Penamine | 6 months stock by reference to usual PBS demand |
8 Schedule 1 (table)
After:
| Ramipril | Tablet 5 mg | Oral | Ramipril Viatris | 6 months stock by reference to usual demand |
insert:
| Ripretinib | Tablet 50 mg | Oral | Qinlock | 6 months stock by reference to usual PBS demand |
Sourced from the Federal Register of Legislation at legislation.gov.au, © Commonwealth of Australia, licensed under CC BY 4.0. Compilations may have been reformatted.